| Name | Title | Contact Details |
|---|
Biesse Group is a global leader in the design, manufacture, and distribution of machinery, integrated systems, components, and software for processing various materials, including wood, glass, stone, plastic, and metal. Founded in 1969 in Pesaro, Italy, the company has grown into a multinational enterprise with around 4,400 employees and a presence in 12 industrial sites and 39 subsidiaries worldwide. Biesse is listed on the STAR segment of the Italian Stock Exchange and exports 90% of its production. The company offers a wide range of solutions, including CNC machining centers, drilling machines, and automated systems tailored for different materials. Biesse emphasizes innovation and sustainability, investing €14 million annually in research and development and holding over 200-250 patents. Its advanced technologies incorporate AI and IoT, supporting industries such as furniture, construction, automotive, aerospace, and shipbuilding. Biesse also provides training and demonstrations through its global network of showrooms and campuses.
Mazars is an internationally integrated partnership, specialising in audit, accountancy, advisory, tax and legal services*. Operating in over 100 countries and territories around the world, we draw on the expertise of more than 50,000 professionals – 33,000+ in Mazars integrated partnership and 17,000+ via the Mazars North America Alliance – to assist clients of all sizes at every stage in their development. *Where permitted under applicable country laws
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
LifeLine Financial captains fast-growing businesses nationwide in service, technology, retail, and trades. We offer exceptional bookkeeping and accounting services nationwide. Call us today and grab a LifeLine (603) 782-4663
GEICO is a Maryland-based financial institution that provides personal and commercial insurance products for individuals and businesses.